Possibly one of the foremost reasons for the concern with mushrooms, is the likely chance for misidentification. Ingesting the wrong kind of mushroom will not only not give the perceived result, but may very well poison its user. Only mushrooms that contain psilocybin will produce the visions and hallucinations that individuals who partake in “magic” mushrooms are looking for. Psilocybin has the ability to yield muscle relaxation and produce hallucinations and visions, which is often the desire of those ingesting these mushrooms. However, caution is flagged because these same mushrooms can also cause severe nausea, extreme pupil dilation, and breathing problems. It is also dangerous because its effects or “trip” cannot be controlled or redirected if it takes a bad turn.
Benzodiazepine therapy can give rise to physiologic and psychologic dependence based on the drug's dosage, duration of therapy and potency. 1 Thus, dependence will develop sooner (such as in one to two months) in a patient who is taking a high dosage of a high-potency agent such as alprazolam than in a patient who is receiving a relatively low dosage of a long-acting, low-potency agent such as chlordiazepoxide. As a result of physiologic dependence, withdrawal symptoms emerge with rapid dose reduction or abrupt discontinuation of the drug.
In any case, there is nonetheless a good deal of evidence to indicate that modafinil is producing at least a portion of its wakefulness-promoting effects by acting as a DRI, or at least via activation of the dopaminergic system. In support of modafinil acting as a dopaminergic agent, its wakefulness-promoting effects are abolished in DAT knockout mice (although it is important to note that DAT knockout mice show D 1 and D 2 receptor and norepinephrine compensatory abnormalities, which might confound this finding), reduced by both D 1 and D 2 receptor antagonists (although conflicting reports exist),  and completely blocked by simultaneous inactivation of both D 1 and D 2 receptors.  In accordance, modafinil shows full stimulus generalization to other DAT inhibitors including cocaine, methylphenidate, and vanoxerine, and discrimination is blocked by administration of both ecopipam (SCH-39166), a D 1 receptor antagonist, and haloperidol , a D 2 receptor antagonist.  Partial substitution was seen with the DRA dextroamphetamine and the D 2 receptor agonist PNU-91356A , as well as with nicotine (which indirectly elevates dopamine levels through activation of nicotinic acetylcholine receptors ).